Page 6,744«..1020..6,7436,7446,7456,746..6,7506,760..»

Stem cell therapy gives dog new lease on life

Posted: Published on June 22nd, 2012

Stem cell therapy has gone to the dogs. The technology aimed at giving ailing pets a new lease on life has arrived in Hawaii. 13-year-old Kumba is still a bit dazed, coming out of general anesthesia. The veterinarian at Surf Paws Animal Hospital just extracted about two tablespoons of fat tissue from the dog. Stem cells from that fat tissue will then be used to help him with his arthritis. "Once we get the stem cells then we do some extra processing steps to wake them up so that they're very active. At the end of that, the veterinarian will inject the stem cells into the areas of damage," says Carol Spangler Vaughn of Medivet America. A company called MediVet America is bringing the technology to animal hospitals in Hawaii. This is a first for Oahu. The company says the procedure works on other animals with different types of ailments. "So the nice thing about this we're not gonna give you a puppy back but we'll give you some nice quality time with your animal. You won't have to put them down because of their arthritis," Vaughn said. Kumba's arthritis had gotten worse in the past five years, and his … Continue reading

Comments Off on Stem cell therapy gives dog new lease on life

MagForce enters into preclinical research agreement to investigate NanoTherm® therapy in the gastrointestinal cancer …

Posted: Published on June 22nd, 2012

Goal is to achieve preclinical proof-of-concept in pancreatic and liver cancer First important milestone to set up a clinical development program with Key Opinion Leaders of the Mayo Clinic and throughout the US A previous pilot study conducted at the Charit, Berlin, has shown feasibility for NanoTherm therapy in patients with pancreatic cancer Berlin, Germany, June 22, 2012 - MagForce AG (Frankfurt, XETRA: MF6), a leading medical device company in the field of nanomedicine with focus on oncology, announced today that the Company has entered into a pre-clinical research agreement with Mayo Clinic (Rochester, MN), a leading US medical center. Under the terms of the agreement, Mayo Clinic will start a research program applying MagForce`s NanoTherm therapy to investigate the preclinical efficacy of the therapy in pancreatic and liver cancer. The project will be directed by Dev Mukhopadhyay, Professor of Biochemistry/Molecular Biology, and the study will be funded by Mayo Clinic. The goal of the project is to achieve preclinical proof-of-concept in order to file the clinical development program supporting the FDA PMA (FDA premarket approval) of the NanoTherm therapy in these indications. "Pancreatic cancer is one of the most aggressive diseases in oncology, ranking fourth among the tumor related … Continue reading

Comments Off on MagForce enters into preclinical research agreement to investigate NanoTherm® therapy in the gastrointestinal cancer …

Stem cell therapy gives dog new lease on life

Posted: Published on June 22nd, 2012

Stem cell therapy has gone to the dogs. The technology aimed at giving ailing pets a new lease on life has arrived in Hawaii. 13-year-old Kumba is still a bit dazed, coming out of general anesthesia. The veterinarian at Surf Paws Animal Hospital just extracted about two tablespoons of fat tissue from the dog. Stem cells from that fat tissue will then be used to help him with his arthritis. "Once we get the stem cells then we do some extra processing steps to wake them up so that they're very active. At the end of that, the veterinarian will inject the stem cells into the areas of damage," says Carol Spangler Vaughn of Medivet America. A company called MediVet America is bringing the technology to animal hospitals in Hawaii. This is a first for Oahu. The company says the procedure works on other animals with different types of ailments. "So the nice thing about this we're not gonna give you a puppy back but we'll give you some nice quality time with your animal. You won't have to put them down because of their arthritis," Vaughn said. Kumba's arthritis had gotten worse in the past five years, and his … Continue reading

Comments Off on Stem cell therapy gives dog new lease on life

Stem cell therapy in Hawaii going to the dogs

Posted: Published on June 22nd, 2012

HAWAII KAI (HawaiiNewsNow) - Cutting-edge technology is helping Hawaii's pets live better lives for months, even years. We were there as a beloved dog named Kumba received one of the first-ever, in-clinic stem cell therapy surgeries in the islands. 13 year old Kumba doesn't know he's a guinea pig. The Rottweiler-Lab mix is one of the first in Hawaii to undergo the stem cell procedure at Surf Paws in Hawaii Kai. Kumba suffers severe arthritis in his hips and knees, doesn't eat much, and is even a bit depressed. "It's an effort for him to get up off the floor, and when he gets up and crosses the room, you can see the stiffness," says his owner, Rumi Hospodar. Kumba's kids learn some of details of his surgery. Then, he's moved to a table and nods off from anesthesia. Once he's prepped, the procedure begins. The vet removes about two tablespoons of fat tissue from Kumba's shoulder. From there, the stem cells are separated from the fat and activated. Then, they're injected back into the affected areas. The entire process takes four hours, but the dog is actually only under for about 20 minutes. Surf Paws used to send the … Continue reading

Comments Off on Stem cell therapy in Hawaii going to the dogs

BioRestorative Therapies Enters Into Brown Fat Research Agreement With University of Utah

Posted: Published on June 22nd, 2012

JUPITER, Fla., June 21, 2012 /PRNewswire/ --BioRestorative Therapies, Inc. ("BRT" or the "Company") (BRTX), a life sciences company focused on cellular therapies for various personal medical applications, announced today that it has entered into a Research Agreement with the University of Utah ("University"). Pursuant to the agreement, the University is to provide research services relating to the identification of brown fat tissue and the development and characterization of brown fat cell lines. Pursuant to the terms of the Research Agreement, all inventions, discoveries, patent rights, information, data, methods and techniques, including all cell lines, cell culture media and derivatives thereof, shall be owned by BRT. The research and development that will be performed at the University, under the supervision of Dr. Amit Patel, will be used for the eventual filing of an IND with the FDA for a Phase 1 clinical trial. The agreement was entered into in connection with the Company's ThermoStem Program, which focuses on treatments for metabolic disorders, such as diabetes and heart disease, and obesity. The ThermoStem Program employs the use of brown fat, which initial research indicates has a role in maintaining metabolism and provides the potential for a cell based therapeutic for the treatment … Continue reading

Posted in FDA Stem Cell Trials | Comments Off on BioRestorative Therapies Enters Into Brown Fat Research Agreement With University of Utah

StemCells, Inc. Initiates Phase I/II Clinical Trial in Dry Age-Related Macular Degeneration

Posted: Published on June 22nd, 2012

NEWARK, Calif., June 21, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (STEM) today announced initiation of a Phase I/II clinical trial of the Company's proprietary HuCNS-SC(R) product candidate (purified human neural stem cells) in dry age-related macular degeneration (AMD) referred to as Geographic Atrophy. There are no approved treatments for dry AMD. The trial is being conducted at the Retina Foundation of the Southwest's (RFSW) Anderson Vision Research Center in Dallas, Texas, one of the leading independent vision research centers in the United States. David G. Birch, Ph.D., Chief Scientific and Executive Officer of the RFSW and Director of the Rose-Silverthorne Retinal Degenerations Laboratory, is the principal investigator of the study. "Dry AMD is the most common form of macular degeneration, and has a very debilitating effect on quality of life," said Dr. Birch. "Transplanting neural stem cells to protect photoreceptors in patients diagnosed with AMD is an innovative, but logical, approach, well supported by the Company's recently published preclinical data. We are very excited to be conducting this trial at RFSW." A summary of the Company's preclinical data was featured in the February 2012 issue of the international peer-reviewed European Journal of Neuroscience (available online at http://onlinelibrary.wiley.com/doi/10.1111/j.1460-9568.2011.07970.x/abstract). The data demonstrated … Continue reading

Posted in Stem Cell Human Trials | Comments Off on StemCells, Inc. Initiates Phase I/II Clinical Trial in Dry Age-Related Macular Degeneration

Ampio Reports Successful Type B Pre-IND Meeting With FDA For Zertane To Treat PE

Posted: Published on June 22nd, 2012

(RTTNews.com) - Ampio Pharmaceuticals, Inc. (AMPE) announced the outcome of its pre-IND meeting with the CDER Urology and Reproductive group division of the U.S. Food and Drug Administration, or FDA, that took place on June 20, 2012. FDA gave all the necessary guidance on the design and conduct of two concurrent phase III pivotal clinical trials of around 15 weeks duration. Successful completion of these trials, powered adequately (based on the phase 3 European trials), will allow for FDA clearance to market Zertane as a treatment for life-long premature ejaculation, or PE. These clinical trials would qualify Zertane's registration/clearance under the 505(b) 2 regulatory pathway in the US, the company noted. Michael Macaluso, Ampio's chief executive officer, said, "We could not be more pleased, as the FDA guidance gave us a clear path to progress our Zertane drug through clinical development rapidly, with procedures that permit prompt resolution of the few outstanding issues, so we could commence the trials by the end of this year. This positive guidance will allow us to formalize our negotiations with potential partners. This productive meeting with the FDA was expected by the company because Zertane already successfully completed two phase II and two phase … Continue reading

Posted in Premature Ejaculation | Comments Off on Ampio Reports Successful Type B Pre-IND Meeting With FDA For Zertane To Treat PE

Ampio Reports Successful Type B Pre-IND Meeting with the FDA for its Drug Zertane™ to treat Premature Ejaculation (PE)

Posted: Published on June 22nd, 2012

GREENWOOD VILLAGE, Colo., June 21, 2012 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (AMPE), a clinical stage biopharmaceutical company, with repurposed drugs and new molecular entities (NMEs) that treat inflammatory diseases, including osteoarthritis, diabetic macular edema (DME) and sexual dysfunction announced today the outcome of its pre-IND meeting with the CDER Urology and Reproductive group (DRUP) division of the FDA that took place on June 20, 2012. The FDA provided all the necessary guidance on the design and conduct of two concurrent phase III pivotal clinical trials of approximately 15 weeks duration. Successful completion of these trials, powered adequately (based on the phase 3 European trials), will allow for FDA clearance to market Zertane as a treatment for life-long premature ejaculation (PE) as defined by the International Society of Sexual Medicine. These clinical trials would qualify Zertane's registration/clearance under the 505(b) 2 regulatory pathway in the US. (Logo: http://photos.prnewswire.com/prnh/20120516/MM09116LOGO) Michael Macaluso, Ampio's CEO, noted, "We could not be more pleased, as the FDA guidance gave us a clear path to progress our Zertane drug through clinical development rapidly, with procedures that permit prompt resolution of the few outstanding issues, so we could commence the trials by the end of this year. This … Continue reading

Posted in Premature Ejaculation | Comments Off on Ampio Reports Successful Type B Pre-IND Meeting with the FDA for its Drug Zertane™ to treat Premature Ejaculation (PE)

Misidentified and contaminated cell lines lead to faulty cancer science

Posted: Published on June 22nd, 2012

Public release date: 20-Jun-2012 [ | E-mail | Share ] Contact: Erika Matich erika.matich@ucdenver.edu 303-524-2780 University of Colorado Denver AURORA, Colo. (June 20, 2012) -AURORA, COLO (June 20, 2012) -- Modern cancer therapies start in cells researchers compare cancer samples to healthy cells to discover how cancer is genetically different, and use cell lines to test promising new drugs. However, a University of Colorado Cancer Center study published this week in the journal Gynecologic Oncology shows that due to a high rate of contamination, misidentification and redundancy in widely available cell lines, researchers may be drawing faulty conclusions. "I've seen faculty and graduate students leave my lab in tears when we discovered the cells on the label weren't the cells they were actually experimenting on," says Christopher Korch, PhD, investigator at the CU Cancer Center and director of the center's DNA Sequencing and Analysis Service, the paper's co-first author. "When you get a cell line, you have to look that gift horse in the mouth there's up to a 40 percent chance it's a Trojan horse, not what it says it is." For example, the cell line known as HES has been widely used as a "normal" model of endometrial … Continue reading

Posted in Cell Medicine | Comments Off on Misidentified and contaminated cell lines lead to faulty cancer science

Enzyme offers new therapeutic target for cancer drugs

Posted: Published on June 22nd, 2012

Public release date: 21-Jun-2012 [ | E-mail | Share ] Contact: Scott LaFee slafee@ucsd.edu 619-543-6163 University of California - San Diego Researchers at the University of California, San Diego School of Medicine have uncovered a new signal transduction pathway specifically devoted to the regulation of alternative RNA splicing, a process that allows a single gene to produce or code multiple types of protein variants. The discovery, published in the June 27, 2012 issue of Molecular Cell, suggests the new pathway might be a fruitful target for new cancer drugs. Signal transduction in the cell involves kinases and phosphatases, enzymes that transfer or remove phosphates in protein molecules in a cascade or pathway. SRPK kinases, first described by Xiang-Dong Fu, PhD, professor of cellular and molecular medicine at UC San Diego in 1994, are involved in controlling the activities of splicing regulators in mammalian cells. Prior studies have implicated SRPK1 in cancer and other human diseases. For example, it has been shown that SRPK1 plays a critical role in regulating the function of Vascular Endothelial Growth Factor or VEGF, which stimulates blood vessel growth in cancer. SRPK1 has been found to be dysregulated in a number of cancers, from kidney and … Continue reading

Posted in Cell Medicine | Comments Off on Enzyme offers new therapeutic target for cancer drugs

Page 6,744«..1020..6,7436,7446,7456,746..6,7506,760..»